Updated Results on Modakafusp Alfa (TAK-573) Safety and Efficacy; Phase 1/2 Study of RRMM Patients

Diagnosis and Therapeutic Advances in Multiple Myeoma

Frontiers Sustained response in early responders to safinamide

Efficacy and safety of elranatamab BCMA-CD3 bispecific antibody

RVd Alone vs Rvd Plus ASCT in Newly Diagnosed Patients

Should smoldering myeloma patients start treatment?

Long-term efficacy and safety of alemtuzumab in patients with RRMS

MODAKAFUSP ALFA (TAK-573), Dan Vogl, MD, MSCE

Nina Shah on X: Modakafusp-alpha: no, not a character from

Updated Results on Modakafusp Alfa (TAK-573) Safety and Efficacy